Clinical Trial

A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a prospective randomized controlled Phase Ⅱ/Ⅲ Clinical study to evaluate the clinical efficacy and safety of Envafolimab combining with Cetuximab -β and mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
Trial Details
NCT Number NCT06959693
Lead Sponsor Sun Yat-sen University
Conditions Metastatic Colorectal Cancer (CRC)
Enrollment 590 participants
Start Date 2025-06-01
Primary Completion 2028-09-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-06